Replies to post #103685 on Innovation Pharmaceuticals Inc (IPIX)

[gostocksgo]

Hot damn!

[BooDog]

I certainly didn't miss any of that, as well as the reactivation. You and others can explain the science a hell of a lot better than me. The wording "blurring the lines" and enabling this to move "faster" is enlightening as well as exciting. I'd like to get as many patients enrolled as we can that fit the profile they're looking for of course. This is excellent news and follows how you've been talking about proceeding. That's why I follow you and a few other science types!

They are submitting an application to the FDA to start a phase 2/3 trial against a specific cancer. Exactly what I posted two days ago, and these past 6 months: a jump to phase 3 against at least one cancer type. This has efficacy and lesion reduction written all over the PR.

I pray it's pancreatic, but will settle for ovarian.

[58nout]

BK when you're right you're right and you have been right about this for as long as I can remember. BEST CALL EVER ON THIS BOARD!

GO BK GO CTIX!!!!

[Rkmatters]

Given p53 is most prevalent in Ovarian (92 % of those cancers), that would be my guess

http://onlinelibrary.wiley.com/store/10.1002/humu.20495/asset/20495_ftp.pdf?v=1&t=i9zfb8jz&s=5a695e1f42e85ca097dce76dd0039dd0d9a8531

[Phoenix300]

Nice call BigKahuna! Go Kevetrin!

[TheHound]

Good call! Very proactive. I hope it's pancreatic as well.

[sox040713]

My guess is ovarian cancer. Besides the lesion disappearance case, CTIX shared an interview by BioCentury TV with the FDA last month. The director of oncology said for future ovarian cancer trials, the FDA is only asking for one arm and overall response rate, instead of the traditional multi-arms and overall survival rate. This will expedite the Kevetrin Phase 2/3 trial tremendously. Imagine administering Kevetrin at 750 mg/m2 daily for multiple consecutive days. The response rate will go through the roof!

I pray it's pancreatic, but will settle for ovarian.